Search the Newsreel

Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...

This article first appeared on GuruFocus. Total Revenues: Approximately $629 million for Q2 2026. Cabozantinib Franchise Net Product Revenues (US): $573 million, up approximately 10% year-over-year. Global Cabozantinib Franchise Net Product Revenues (Exelixis and partners): $806 million, up approximately 13% year-over-year. CABOMETYX Net Product …

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Exelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS

Exelixis reported strong Q2 2026 earnings, with revenue reaching $628.7 million, a 10.6% increase year-over-year, and diluted EPS rising to $0.82. This growth was primarily driven by higher sales volume of cabozantinib, though the company lowered its full-year revenue outlook. Exelixis continues to invest …

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Exelixis reported strong second-quarter 2026 financial results, with total revenues reaching $628.7 million and GAAP diluted EPS of $0.82. The company highlighted the continued growth of its cabozantinib franchise and significant progress in its zanzalintinib development program, including ongoing regulatory review for metastatic colorectal …

Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026

This article is a transcript of Exelixis, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. During the call, Exelixis updated its fiscal 2026 revenue guidance to $2.50B-$2.55B, lower than FactSet's estimate of $2.60B. The company also reported Q2 revenue of $628.7M and …

Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M

Exelixis, Inc. (EXEL) reported its Q2 revenue at $628.7 million, falling short of the FactSet estimate of $636.4 million. The company also updated its fiscal year 2026 revenue guidance to a range of $2.50 billion to $2.55 billion, which is below the FactSet estimate …

Exelixis earnings on deck as generic threat looms

Exelixis Inc. is set to report second-quarter earnings, facing scrutiny over its flagship cancer drug, Cabometyx, due to an escalating patent dispute and the emergence of a generic alternative. Investors are also keenly watching the commercialization prospects for its next-generation pipeline drug, zanzalintinib, and …

Royal Bank of Canada Grows Stock Holdings in Exelixis, Inc. $EXEL

Royal Bank of Canada increased its holdings in Exelixis, Inc. by 24.6% in the first quarter, now owning 694,131 shares valued at approximately $29.8 million. This increase comes as Exelixis reported strong quarterly earnings, beating analyst estimates, with revenue up 10% year-over-year. Despite recent …

Telix to Host R&D Day in New York City on September 22, 2026

Telix Pharmaceuticals Limited will host an R&D Day in New York City on September 22, 2026, for institutional investors and analysts, providing an overview of its therapeutic and precision medicine pipeline. The event will feature presentations from Telix's leadership and key opinion leaders. Additionally, …

Telix R&D Day to Feature Pipeline Updates and Outside Experts

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) will host an in-person Research and Development Day in New York City on September 22, 2026, for institutional investors and analysts to discuss its therapeutic and precision medicine pipeline. The event will feature presentations from senior leadership and …

Helix Energy Solutions Group, Inc. $HLX Stake Increased by Janus Henderson Group PLC

Janus Henderson Group PLC significantly increased its stake in Helix Energy Solutions Group (NYSE:HLX) during the first quarter, purchasing an additional 992,261 shares and now owning 1.06 million shares valued at $10.4 million. Other institutional investors like Quarry LP, Royal Bank of Canada, Aaron …

Exelixis (EXEL) Stock Still Looks Cheap On Earnings While Returns Look Rich

Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Elixirr International Plc Revenue Breakdown – LSE:ELIX

Class Action Alert: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. (TLX) Investors of January 9, 2026 Deadline

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding …

Exelixis, Inc. $EXEL Shares Sold by Private Client Services LLC

Private Client Services LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 40.9% in the second quarter, selling 19,576 shares. Despite this, Exelixis reported strong quarterly earnings of $0.87 per share, surpassing estimates, with revenue increasing 10% year over year to $610.81 million. The …

Delixy Holdings director Ye Changkun files initial beneficial ownership statement

Delixy Holdings director Ye Changkun has filed an initial Form 3 insider ownership statement dated July 30. This news brief, generated by AI, clarifies that Delixy Holdings Ltd. is responsible for the original content filed via EDGAR. The article emphasizes that the content reflects …

Helix Energy Solutions Group Inc expected to post earnings of 7 cents a share - Earnings Preview

Helix Energy Solutions Group Inc (HLX) is anticipated to report earnings of 7 cents per share. This article is an earnings preview from Reuters, accessible through TradingView.

Exelixis Inc expected to post earnings of 79 cents a share - Earnings Preview

Exelixis Inc. is anticipated to report earnings of 79 cents per share. This information is provided as an earnings preview from Reuters, accessible via TradingView. The full article is available with unlimited access on TradingView.

Elixirr earnings hike; Winvia-Aston Villa tie-up

HELIX ENERGY SOLUTIONS GROUP INC SEC Filing (Aug 3, 2026)

This article reports on an SEC filing (Form EFFECT) by HELIX ENERGY SOLUTIONS GROUP INC (HLX) on August 3, 2026. The filing indicates the effectiveness of an S-4 registration statement on July 31, 2026, at 3:30 P.M. It includes links to the original filing …

Exelixis stock rating maintained at Market Outperform by Citizens

Citizens has maintained a Market Outperform rating and a $55.00 price target for Exelixis (NASDAQ:EXEL), noting that the stock appears undervalued according to InvestingPro analysis. The article also discusses the ongoing patent dispute between Exelixis and Handa Oncology regarding a new cabozantinib formulation and …

Arrowstreet Capital Limited Partnership Acquires 240,414 Shares of Helix Energy Solutions Group, Inc. $HLX

Arrowstreet Capital Limited Partnership significantly increased its stake in Helix Energy Solutions Group (HLX) by 71.2% in the first quarter, adding 240,414 shares to now hold 577,979 shares valued at $5.7 million. This move is part of a broader trend where institutional investors own …

Elixir Energy’s Lorelle-3H Flow Test Confirms Taroom Trough Gas Potential

Elixirr International (ELIX) Achieves Record £89m H1 2026 Revenue, Up 25%, and Names Canaccord Genuity as Joint Broker

Elixirr shares climb 9% on record half as AI consulting demand builds

How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Upgraded FY26 Guidance And Pipeline Milestones

Helix Energy Solutions Group (HLX) Rides Decommissioning Story With Fair Value Still In View

Exelixis, Inc. Revenue Breakdown – NASDAQ:EXEL

Exelixis, Inc. (EXEL) generated $2.32 billion in revenue last year, primarily from its "Medicines for Difficult-to-treat Cancers" segment. This represents an increase from $2.17 billion in the previous year. The United States was the largest contributor to revenue, accounting for $2.14 billion.

Helix Resources Expands West Pilbara Gold–Lithium Footprint and Restructures Capital

Q3 2025 Helix Energy Solutions Group Inc Earnings Call Transcript

Helix Energy Solutions Group Inc (HLX) reported strong Q3 2025 results, achieving its highest quarterly revenues since 2014 at $377 million and a net income of $22 million, alongside robust cash and liquidity positions. The Robotics segment performed exceptionally well with high vessel utilization …

Helix Energy Sol Group Number of Employees 2026 | Employee Count & Headcount Data

Helix Energy Solutions Group, Inc. (HLX) had approximately 2,249 employees globally as of March 2026, marking a 0.9% growth from 2023 but a 1.5% year-over-year decrease. The company is actively hiring with 29 job postings in 2026, a significant increase from 2025. Its workforce …

Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis

Exelixis Inc (EXEL) has a strong financial health score of 8.96, ranking 22nd in the Biotechnology & Medical Research industry. The company reported a quarterly revenue of $610.81 million, marking a 9.97% year-over-year increase, and its net profit rose by 31.86% year-over-year. This indicates …

HLX|Helix Energy Solutions Group Inc|Price:9.210|Chg%:+0.140

This article provides a comprehensive stock analysis of Helix Energy Solutions Group Inc (HLX) from TradingKey, highlighting its strong fundamentals, good growth potential, and fair valuation within the Oil & Gas Related Equipment and Services industry. It notes high institutional ownership and recent "Buy" …

Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat (NASDAQ:TLX)

Exelixis (EXEL) Slides as Investors Likely Take Profits Ahead of Earnings